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Background. A number of western studies have suggested that the 6-month duration requirement of generalized
anxiety disorder (GAD) does not represent a critical threshold in terms of onset, course, or risk factors of the
disorder. No study has examined the consequences of modifying the duration requirement across a wide range of
correlates in both developed and developing countries.
Method. Population surveys were carried out in seven developing and 10 developed countries using the WHO
Composite International Diagnostic Interview (total sample=85 052). Prevalence and correlates of GAD were
compared across mutually exclusive GAD subgroups defined by different minimum duration criteria.
Results. Lifetime prevalence estimates for GAD lasting 1 month, 3 months, 6 months and 12 months were 7.5%,
5.2%, 4.1% and 3.0% for developed countries and 2.7%, 1.8%, 1.5% and 1.2% for developing countries, respectively.
There was little difference between GAD of 6 months’ duration and GAD of shorter durations (1–2 months, 3–5
months) in age of onset, symptom severity or persistence, co-morbidity or impairment. GAD lastingo12 months was
the most severe, persistently symptomatic and impaired subgroup.
Conclusions. In both developed and developing countries, the clinical profile of GAD is similar regardless of
duration. The DSM-IV 6-month duration criterion excludes a large number of individuals who present with shorter
generalized anxiety episodes which may be recurrent, impairing and contributory to treatment-seeking. Future
iterations of the DSM and ICD should consider modifying the 6-month duration criterion so as to better capture the
diversity of clinically salient anxiety presentations.
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Introduction
Generalized anxiety disorder (GAD) is increasingly
recognized as a prevalent anxiety disorder with
characteristic symptoms, significant morbidity and
specific risk factors (WHO, 1993; APA, 2000). Never-
theless, repeated revisions of the GAD diagnostic cri-
teria in recent decades reflect continued uncertainty
over the definition and diagnosis of the disorder.
Apart from debates over the centrality of pathological
worry, the number and type of associated anxiety
symptoms, and the level of impairment required for
diagnosis (Spitzer & Williams, 1984 ; Rickels & Rynn,
2001 ; Slade & Andrews, 2001), a primary focus for
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nosological revision has been the duration criterion of
GAD. Although early classifications of pathological
anxiety did not specify a minimum duration for diag-
nosis (Feighner et al. 1972 ; WHO, 1978), efforts to im-
prove diagnostic reliability and differentiation from
normal anxiety reactions led to the requirement of a
minimum GAD duration of 1 month in the Diagnostic
and Statistical Manual of Mental Disorders, 3rd edn
(DSM-III, APA, 1980) and an increase to 6 months in
the revised DSM-III-R (APA, 1987), the DSM-IV (APA,
2000) and the Diagnostic Criteria for Research of the
International Classification of Mental and Behavioral
Disorders, 10th edn (ICD-10, WHO, 1993).
Among the anxiety disorders, the requirement of
such a long and specific duration is almost unique to
GAD, and questions about its necessity remain. This
suggests that, despite improved reliability of diagnosis
(Brown et al. 2001), questions about the validity of
GAD are by no means resolved. Following criticisms
of the questionable clinical utility of the current dur-
ation criterion in defining GAD (Rickels & Rynn,
2001), a number of empirical studies in western
countries have recently addressed this question. Taken
together, they suggest that GAD lasting 1 month
is comparable to GAD lasting o6 months in socio-
demographic characteristics, clinical course, pattern of
co-morbidity, functional impairment, antecedent
childhood adversity, and heritability (Kendler et al.
1992, 1994 ; Bienvenu et al. 1998; Maier et al. 2000 ;
Carter et al. 2001 ; Hettema et al. 2001 ; Kessler et al.
2005 ; Angst et al. 2006).
Such findings have prompted calls for shortening
the duration criterion of GAD in DSM-V (Bienvenu
et al. 1998 ; Rickels & Rynn, 2001 ; Kessler et al. 2005 ;
Angst et al. 2006 ; Ruscio et al. 2007). Before this change
can be considered seriously, however, additional data
are needed on at least two fronts. First, the GAD dur-
ation criterion originally was increased from 1 to 6
months because of concerns that the shorter duration
did not adequately distinguish GAD from normative,
transient reactions to stress (Breslau & Davis, 1985).
Similar concerns about reduced diagnostic validity
and pathologizing of normal stress reactions are likely
to be raised for DSM-V. Addressing these concerns
will require systematic comparisons of GAD of vary-
ing durations on a wide range of relevant validators.
Second, although the DSM aspires to be a global di-
agnostic system, empirical studies of the GAD criteria
outside of western countries have been scarce.
Recently published data from developing countries
such as Nigeria and China have begun to address
this gap, but have so far been confined to reporting
basic prevalence estimates and sociodemographic cor-
relates of GAD based only on DSM-IV diagnostic cri-
teria (Gureje et al. 2006 ; Shen et al. 2006) rather than
evaluating the impact of modifying these criteria. It
is therefore desirable to evaluate how varying the
duration of GAD may affect its validity in a range of
developed and developing countries, ideally using
unselected, general population samples to minimize
the impact of sampling biases on results.
The present study examined the validity of GAD
defined by different durations in a large dataset in-
cluding representative samples from 10 developed
and seven developing countries. After estimating the
prevalence of GAD defined by different minimum
duration criteria (1 month, 3 months, 6 months,
12 months), we compared the characteristics of four
mutually exclusive groups that met the symptom cri-
teria for DSM-IV GAD but differed in the duration of
their longest GAD episode.
Method
Samples
As part of the World Health Organization’s World
Mental Health (WMH) Survey Initiative (Demyt-
tenaere et al. 2004), 17 countries in the Americas
(Colombia, Mexico, USA), Europe (Belgium, France,
Germany, Italy, the Netherlands, Spain), Ukraine, the
Middle East (Israel, Lebanon), Africa (Nigeria, South
Africa) and Asia-Pacific (Japan, New Zealand,
People’s Republic of China – Beijing, Shanghai) were
surveyed. Developing countries were those with a
human development index <0.90, namely China
(Beijing, Shanghai), Colombia, Lebanon, Mexico,
Nigeria, South Africa and Ukraine. Developed
countries were those with a human development
index of o0.90, namely Belgium, France, Germany,
Israel, Italy, Japan, the Netherlands, New Zealand,
Spain and the USA (United Nations Development
Programme, 2004).
All surveys were based on multi-stage, clustered
area probability household samples. Interviews were
carried out face to face by trained lay interviewers. The
combined total sample size was 85 052 (Table 1). Most
of the respondents were agedo18 years, with the ex-
ception of respondents from New Zealand (agedo16
years), Japan (aged o20 years) and Israel (aged o21
years). Survey response rates varied, with a weighted
average response rate across surveys of 71%. Other
than in the Israel survey, where all respondents were
administered the full interview, internal subsampling
was used to reduce respondent burden by dividing
the interview into two parts. Part 1 assessed core
mental disorders, including GAD, and was adminis-
tered to all respondents. Part 2 included additional
disorders and correlates relevant to a wide range
of survey aims. It was administered to all part 1
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respondents who met criteria for any mental disorder
as well as a probability sample of other respondents.
Part 2 respondents were weighted by the inverse of
their probability of selection for part 2 of the interview
to adjust for differential sampling. Additional weights
were used to adjust for differential probabilities of
selection within households and to match the samples
to population sociodemographic distributions.
Training and field procedures
The central WMH staff trained bilingual supervisors
in each country. Consistent interviewer training
documents and standardized translation protocols
were used across surveys. The institutional review
board of the organization that coordinated the survey
in each country approved and monitored compliance
with procedures for obtaining informed consent and
protecting human subjects.
Diagnostic measures
Mental disorders were assessed using version 3.0
of the World Health Organization Composite In-
ternational Diagnostic Interview (CIDI) (Kessler &
Ustun, 2004), a fully structured lay-administered in-
terview that generates diagnoses according to both
ICD-10 (WHO, 1993) and DSM-IV criteria. DSM-IV
anxiety, mood and substance-use disorders were in-
cluded in analyses, as were several disorders that
share a common feature of difficulties with impulse
control (intermittent explosive disorder, oppositional-
deviant disorder, conduct disorder, attention-deficit
hyperactivity disorder). Diagnostic hierarchy rules
and organic exclusion rules were used in making
diagnoses. As detailed elsewhere (Haro et al. 2006),
blind clinical re-interviews using the Structured Clini-
cal Interview for DSM-IV (SCID, First et al. 2002) with
a probability subsample of respondents from Spain,
Italy, France and the USA found generally good con-
cordance between DSM-IV diagnoses based on the
CIDI and the SCID for anxiety (including GAD), mood
and substance-use disorders (CIDI diagnoses of
impulse-control disorders were not validated).
Respondents were assessed for the symptoms of
GAD, and then asked about the number and length of
episodes of worry or anxiety experienced in their life-
time and in the last 12 months. ‘Episode’ was ex-
plicitly defined as ‘a time lasting 1 month or longer
when most days you were (worried or anxious/
nervous or anxious/anxious or worried) and also had
some of the other problems we just reviewed. The
episode ends when you no longer have these feelings
for a full month. ’ Respondents reporting multiple
episodes were grouped for analysis based on their
longest lifetime episode.
Other measures
Impairment was assessed by the Sheehan Disability
Scale (SDS, Leon et al. 1997), which asked respondents
to focus on the 1 month in the past year when their
GAD was most severe and to rate how much GAD
interfered with their home management, work, social
life and personal relationships on scales of none (0),
mild (1–3), moderate (4–6), severe (7–9) and very se-
vere (10). In addition, role impairment in the past year
was assessed by two variables : number of out-of-
role days, defined as the number of days out of 365
during which the respondent was ‘ totally unable ’ to
work or carry out daily activities because of GAD; and
role impairment in episode, defined as the percentage
of all days in the GAD episode that were spent out of
role.
Analysis methods
We estimated the 1-month, 12-month and lifetime
prevalence of GAD using the minimum duration re-
quirements of 1, 3, 6 and 12 months. Subsequently,
mutually exclusive subgroups with durations of 1–2,
3–5, 6–11 and o12 months were compared on age of
onset, clinical course, persistence, role impairment and
time to recovery using x2 tests or analysis of variance.
Associations with other mental disorders were esti-
mated using a discrete-time survival model with
person-year as the unit of analysis, in which variably
defined GAD predicted the subsequent first onset of a
class of disorders (other anxiety disorders, mood dis-
orders, substance-use disorders, impulse-control dis-
orders). We used the actuarial method (Halli &
Vaninadha Rao, 1992) to calculate age-of-onset (AOO)
and time to recovery curves for these duration sub-
groups. Using the Taylor series linearization method
(Wolter, 1985) implemented in the SUDAAN software
package (Research Triangle Institute, Research
Triangle Park, NC, USA), we adjusted for weighting
and clustering when calculating standard errors and
performing significance tests. Statistical significance
was evaluated at the 0.05 level.
Results
Prevalence
The estimated prevalence of GAD increased as the
duration criterion was shortened. (Table 2) For devel-
oped countries, lifetime prevalence estimates ranged
from a low of 3.0% when the minimum duration was
12 months to a high of 7.5% when the minimum
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Table 1. WMH sample characteristics
Country Survey Sample characteristicsa
Field
dates
Age
range,
years
Sample size
Response
ratecPart 1 Part 2
Part 2 and age
f44 yearsb
Developed
Belgium ESEMeD Stratified multi-stage clustered probability sample of individuals residing
in households from the national register of Belgium residents. NR
2001–2 o18 2419 1043 486 50.6
France ESEMeD Stratified multi-stage clustered sample of working telephone numbers
merged with a reverse directory (for listed numbers). Initial recruitment
was by telephone, with supplemental in-person recruitment in
households with listed numbers. NR
2001–2 o18 2894 1436 727 45.9
Germany ESEMeD Stratified multi-stage clustered probability sample of individuals from
community resident registries. NR
2002–3 o18 3555 1323 621 57.8
Israel NHS Stratified multi-stage clustered area probability sample of individuals
from a national resident register. NR
2002–4 o21 4859 – – 72.6
Italy ESEMeD Stratified multi-stage clustered probability sample of individuals from
municipality resident registries. NR
2001–2 o18 4712 1779 853 71.3
Japan WMHJ2002–2006 Unclustered two-stage probability sample of individuals residing in
households in nine metropolitan areas (Fukiage, Higashi-ichiki, Ichiki,
Kushikino, Nagasaki, Okayama, Sano, Tamano, Tendo and Tochigi)
2002–6 o20 3417 1305 425 59.2
Netherlands ESEMeD Stratified multi-stage clustered probability sample of individuals residing
in households that are listed in municipal postal registries. NR
2002–3 o18 2372 1094 516 56.4
New Zealand NZMHS Stratified multi-stage clustered area probability sample of household
residents. NR
2004–5 o16 12992 7435 4242 73.3
Spain ESEMeD Stratified multi-stage clustered area probability sample of household
residents. NR
2001–2 o18 5473 2121 960 78.6
USA NCS-R Stratified multi-stage clustered area probability sample of household
residents. NR
2002–3 o18 9282 5692 3197 70.9
Developing
Colombia NSMH Stratified multi-stage clustered area probability sample of household
residents in all urban areas of the country (approximately 73% of the
total national population)
2003 18–65 4426 2381 1731 87.7
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Lebanon LEBANON Stratified multi-stage clustered area probability sample of household
residents. NR
2002–3 o18 2857 1031 595 70.0
Mexico M-NCS Stratified multi-stage clustered area probability sample of household
residents in all urban areas of the country (approximately 75% of the
total national population)
2001–2 18–65 5782 2362 1736 76.6
Nigeria NSMHW Stratified multi-stage clustered area probability sample of households
in 21 of the 36 states in the country, representing 57% of the national
population. The surveys were conducted in Yoruba, Igbo, Hausa and
Efik languages
2002–3 o18 6752 2143 1203 79.3
People’s
Republic
of China
B-WMH
S-WMH
Stratified multi-stage clustered area probability sample of
household residents in the Beijing and Shanghai metropolitan areas
2002–3 o18 5201 1628 570 74.7
South Africa SASH Stratified multi-stage clustered area probability sample of
household residents. NR
2003–4 o18 4351 – – 87.1
Ukraine CMDPSD Stratified multi-stage clustered area probability sample of
household residents. NR
2002 o18 4725 1720 541 78.3
WMH, World Mental Health ; ESEMeD, The European Study of the Epidemiology of Mental Disorders ; NR, nationally representative ; NHS, Israel National Health Survey ;
WMHJ2002–2006, World Mental Health Japan Survey ; NZMHS, New Zealand Mental Health Survey ; NCS-R, The US National Comorbidity Survey Replication ; NSMH, The Colombian
National Study of Mental Health ; LEBANON, Lebanese Evaluation of the Burden of Ailments and Needs of the Nation ; M-NCS, TheMexico National Comorbidity Survey ; NSMHW, The
Nigerian Survey of Mental Health andWellbeing ; B-WMH, The BeijingWorldMental Health Survey ; S-WMH, The Shanghai WorldMental Health Survey ; SASH, South Africa Stress and
Health Study ; CMDPSD, Comorbid Mental Disorders during Periods of Social Disruption.
aMost WMH surveys are based on stratified multi-stage clustered area probability household samples in which samples of areas equivalent to counties or municipalities in the USA
were selected in the first stage followed by one or more subsequent stages of geographic sampling (e.g. towns within counties, blocks within towns, households within blocks) to arrive at a
sample of households, in each of which a listing of household members was created and one or two people were selected from this listing to be interviewed. No substitution was allowed
when the originally sampled household resident could not be interviewed. These household samples were selected from census area data in all countries other than France (where
telephone directories were used to select households) and the Netherlands (where postal registries were used to select households). Several WMH surveys (Belgium, Germany and Italy)
used municipal resident registries to select respondents without listing households. The Japanese sample is the only totally unclustered sample, with households randomly selected in
each of the four sample areas and one random respondent selected in each sample household. Eleven of the seventeen surveys are based on nationally representative household samples,
while two others are based on nationally representative household samples in urbanized areas (Colombia, Mexico).
b Israel and South Africa did not have an age-restricted part 2 sample. All other countries, with the exception of Nigeria, People’s Republic of China and Ukraine (which were age
restricted tof39 years) were age restricted tof44 years.
c The response rate is calculated as the ratio of the number of households in which an interview was completed to the number of households originally sampled, excluding from the
denominator households known not to be eligible either because of being vacant at the time of initial contact or because the residents were unable to speak the designated languages of the
survey.
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duration was 1 month. The corresponding estimates
for developing countries were lower, but in the same
direction, ranging from 1.2% for 12-month to 2.7%
for 1-month minimum duration. The same pattern
was evident for 12-month prevalence estimates for
developed (1.3–3.2%) and developing (0.7–1.4%)
countries as well as for 1-month estimates in both
country groups (developed 0.6–1.1%, developing 0.3–
0.6%).
Onset and course
Cumulative AOO distributions were similar in shape
for the four mutually exclusive duration subgroups,
although the distributions differed significantly [de-
veloped x2(3)=26.0, developing x2(3)=18.0, p<0.01]
(Fig. 1). In both groups of countries, all four subgroups
had median AOO in the thirties and rarely had onsets
after age 60 years. Mean AOO was also quite similar
among the subgroups, falling in the age range of 25–30
years (Table 3). In developed countries, the 1–2
months subgroup had a somewhat later onset than the
other three subgroups. In developing countries, there
was no significant difference in mean AOO by sub-
group.
GAD lastingo12 months exhibited greater persist-
ence than the other subgroups. In both developed and
developing countries, this subgroup reported more
years with GAD (8.7, 6.5) than the other subgroups,
which were more similar to one another (5.3–5.7, 3.5–
4.4). Increasing duration of GAD was associated not
only with an increase in the longest lifetime GAD
episode, but also with more months in episode during
the past year. By contrast, the four subgroups did not
differ in annual persistence of GAD (the proportion of
lifetime cases that had GAD in the past 12 months).
The subgroups also did not differ in lifetime persist-
ence of GAD, as they all experienced generalized
Table 2. Lifetime, 1-year and 1-month prevalence estimates of DSM-IV generalized anxiety
disorder when the duration threshold was set at the minimal requirement of 1, 3, 6 and
12 months, in developing and developed countries
Prevalence of GAD when minimal duration
threshold is set at …
1 month 3 months
6 months
(DSM-IV criterion) 12 months
Developed countries
1 month 1.1 (0.1) 0.8 (0.0) 0.7 (0.0) 0.6 (0.0)
12 months 3.2 (0.1) 2.2 (0.1) 1.7 (0.1) 1.3 (0.1)
Lifetime 7.5 (0.2) 5.2 (0.2) 4.1 (0.1) 3.0 (0.1)
Developing countries
1 month 0.6 (0.1) 0.4 (0.1) 0.4 (0.1) 0.3 (0.0)
12 months 1.4 (0.1) 1.0 (0.1) 0.8 (0.1) 0.7 (0.1)
Lifetime 2.7 (0.1) 1.8 (0.1) 1.5 (0.1) 1.2 (0.1)
DSM-IV, Diagnostic and Statistical Manual of Mental Disorders, 4th edn ; GAD,
generalized anxiety disorder.
Values are given as percentage (standard error).
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Fig. 1. Age of onset of generalized anxiety disorder in
(a) developed countries (x2=26.0, p<0.01) and (b) developing
countries (x2=18.0, p<0.01). -'-, 1–2 months ; -&-, 3–5
months ; -m-, 6–11 months ; -r-, 12 months.
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anxiety in roughly half of the years since the onset of
their respectively defined GAD.
Severity and impairment
Lifetime GAD severity (mild, moderate, severe) was
calculated by submitting 11 nested dichotomous vari-
ables representing uncontrollability, distress, and im-
pairment associated with worry and generalized
anxiety into an item response theory analysis and tri-
chotomizing the resulting dimension. There was a
significant trend in developed [x2(6)=110.5, p<0.01]
as well as developing [x2(6)=20.7, p<0.01] countries
of fewer mild cases and more severe cases with in-
creasing GAD duration (results not shown, but avail-
able on request). The highest proportion of severe
cases was in the o12 months subgroup in both de-
veloped (41.7%) and developing (36.7%) countries.
Nevertheless, severity was substantial even in the 1–2
months subgroup, where the majority of cases (55.9%
in developed and 60.6% in developing countries) were
classified as having moderate or severe GAD.
Impairment was also related to duration of GAD
(Table 4). In developed countries, the o12 months
subgroup was more severely impaired on all SDS
domains (4.1–4.7) than the 1–2 months subgroup (3.4–
3.8), with the 3–5 and 6–11 months subgroups being
intermediate in impairment. Although they differed
significantly, the subgroup means for each domain
and for the highest-rated domain were within one
point of each other on the 0–10 response scale. There
was a larger difference between theo12 months sub-
group (48.2) and the other subgroups (15.8–24.7) on
number of out-of-role days due to GAD. In developing
countries, the overall pattern was also that impairment
increased with increasing duration, although the in-
crease was less monotonic than the pattern shown in
developed countries. This increasing pattern was
statistically significant only for social impairment and
for days out of role, where the largest difference was
Table 3. Course of lifetime GAD by specific episode duration (1–2 months, 2–5 months, 6–11 months,o12 months), in developed and
developing countries
Duration of generalized anxiety
F test
(df=3) p1–2 months 3–5 months 6–11 months o12 months
Developed countries
n 1128 557 604 1603
Mean age of onset, years (S.E.) 26.7 (0.5) 28.9 (0.7) 30.1 (0.7) 28.9 (0.4) 25.8* <0.01
Mean number of years with GAD (S.E.) 5.7 (0.3) 5.6 (0.5) 5.3 (0.4) 8.7 (0.3) 55.7* <0.01
Proportion of years with GAD since onseta (S.E.) 0.7 (0.1) 0.7 (0.1) 0.6 (0.1) 0.7 (0) 2.5 0.48
Mean longest duration of GAD, months (S.E.) 1.4 (0) 3.4 (0) 6.8 (0.1) 80.6 (3.9) 457.1* <0.01
Annual persistence of GADb 41.8 (1.9) 44.2 (2.4) 41.4 (2.3) 42.7 (1.5) 5.5 0.14
Mean number of months in previous year (S.E.)
with anxiety among those with GAD in
previous year
3.0 (0.2) 3.8 (0.2) 5.2 (0.3) 7.2 (0.2) 272.1* <0.01
np 474 248 251 363
Developing countries
n 301 109 108 432
Mean age of onset, years (S.E.) 25.2 (0.8) 25.8 (1.3) 26.6 (0.7) 29.8 (0.8) 0.5 0.92
Mean number of years with GAD (S.E.) 3.7 (0.3) 3.5 (0.5) 4.4 (0.6) 6.5 (0.5) 14.9* <0.01
Proportion of years with GAD since onseta (S.E.) 0.6 (0.1) 0.6 (0.1) 0.5 (0.1) 0.5 (0) 1.2 0.74
Mean longest duration of GAD, months (S.E.) 1.3 (0) 3.4 (0.1) 6.8 (0.1) 92 (7.5) 148.9* <0.01
Annual persistence of GADb 53.1 (3.4) 42.6 (5.5) 54.8 (5.4) 56.4 (2.8) 5.4 0.14
Mean number of months in previous year (S.E.)
with anxiety among those with GAD in
previous year
3.2 (0.3) 3.5 (0.4) 5 (0.5) 6.4 (0.3) 37.1* <0.01
np 157 52 54 251
GAD, Generalized anxiety disorder ; df, degrees of freedom; S.E., standard error ; np, number of respondents with GAD in
previous 12 months.
a Number of years in episode divided by the total years between onset age of generalized anxiety and current age.
b Percentage of lifetime cases that had generalized anxiety in the past 12 months (ratio of 12-month to lifetime
prevalencer100%).
* Significant at p<0.05.
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between the 1–2 months subgroup (10.8) and the other
subgroups (24.4–30.8).
Co-morbidity and suicidality
All four GAD subgroups were significantly associated
with the subsequent first onset of other mental dis-
orders (Table 5). Where significant differences existed,
the highest odds of subsequent disorders were found
for theo12 month subgroup. Differences between the
other subgroups were generally non-monotonic across
disorder classes and inconsistent across developed
and developing countries. In predicting the onset of
any co-morbid mental disorder, only theo12 months
subgroup differed significantly from the 1–2 months
subgroup in developed countries by exhibiting higher
associations with other anxiety disorders and with
any mood disorders. None of the subgroups differed
significantly in developing countries. In follow-up
analyses examining past-year co-morbidity of GAD
with individual mental disorders, the four subgroups
had elevated odds ratios (ORs) with every anxiety and
mood disorder assessed in the surveys, as well as with
intermittent explosive disorder and alcohol abuse
(results available on request).
In contrast to GAD of shorter durations, the o12
months subgroup had a significantly elevated risk
of suicidality (results not shown, but available on
request). The ORs in developed and developing
countries were significant for subsequent suicidal
ideation (2.0, 2.0), plan (1.7, 2.0) and attempt (1.6, 2.1).
The ORs for the other GAD subgroups were non-
significant and non-monotonic.
Treatment and recovery
Duration of GAD in the prior 12-month period was
unrelated to 12-month treatment for the disorder
(results not shown, but available on request). In de-
veloped countries, the lifetime treatment rate for GAD
was significantly lower for the 1–2 months subgroup
(46.3%) than for the other subgroups (50.7–53.9%),
Table 4. Past-year impairment in Sheehan Disability Scale domains and days out of role among respondents with lifetime GAD defined
by specific episode duration (1–2 months, 2–5 months, 6–11 months,o12 months), in developed and developing countriesa
Duration of generalized anxiety
F test,
df=3 p1–2 months 3–5 months 6–11 months o12 months
Developed countries
np 474 248 251 363
Homeb 3.4 (0.2) 3.6 (0.2) 3.7 (0.2) 4.1 (0.2) 12.0* 0.01
Workb 3.7 (0.2) 4.0 (0.3) 3.7 (0.2) 4.3 (0.2) 10.7* 0.01
Relationshipsb 3.8 (0.2) 4.3 (0.3) 4.6 (0.2) 4.7 (0.2) 18.8* <0.01
Social lifeb 3.7 (0.2) 4.2 (0.3) 4.3 (0.2) 4.4 (0.2) 19.3* <0.01
Highest-rated domainb 5.2 (0.2) 6.1 (0.2) 5.8 (0.2) 6.2 (0.2) 24.5* <0.01
Days out of rolec 15.8 (2.7) 24.7 (4.7) 21.3 (4) 48.2 (4.6) 39.9* <0.01
Role impairment in episoded (S.E.) 0.1 (0.0) 0.2 (0.0) 0.1 (0.0) 0.2 (0.0) 13.0* 0.01
Developing countries
np 157 52 54 251
Homeb 2.5 (0.3) 3.4 (0.5) 3.4 (0.5) 3.9 (0.3) 7.7 0.05
Workb 2.7 (0.3) 3.1 (0.6) 4.0 (0.6) 3.1 (0.3) 5.1 0.16
Relationshipsb 3.0 (0.4) 3.4 (0.5) 3.8 (0.7) 3.0 (0.3) 6.4 0.09
Social lifeb 3.2 (0.4) 3.4 (0.6) 4.6 (0.6) 3.4 (0.3) 8.8* 0.03
Highest-rated domainb 4.3 (0.4) 4.9 (0.6) 5.5 (0.5) 4.9 (0.3) 9.0* 0.03
Days out of rolec 10.8 (2.8) 24.4 (11) 30.8 (10) 29.3 (5.2) 10.3* 0.02
Role impairment in episoded (S.E.) 0.1 (0.0) 0.2 (0.1) 0.2 (0.1) 0.1 (0.0) 3.0 0.39
GAD, Generalized anxiety disorder ; df, degrees of freedom; np, number of respondents with GAD in previous 12 months ;
S.E., standard error.
a Estimated among 12-month cases (np).
bMean (S.E.) on the Sheehan Disability Scale, which was rated on a scale of 0 (no impairment), 1–3 (mild), 4–6 (moderate),
7–9 (severe), 10 (very severe impairment).
cMean (S.E.) number of days in the past 12 months during which the respondent was ‘ totally unable ’ to work or carry out
daily activities because of GAD.
d In the past 12 months, proportion of days with GAD that respondents were out of role for the whole day.
* Significant at p<0.05.
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although the proportions were not very different in
substantive terms. Duration was not associated with
lifetime treatment in developing countries [Wald x2 (3)
=2.7, p=0.4], probably because of the low preva-
lence of GAD and rates of treatment there (18.5–
31.4%).
In terms of recovery from GAD, defined as two or
more continuous years without symptoms among
lifetime cases, the duration subgroups differed from
one another significantly for both country groups [de-
veloped x2(3)=26.0, developing x2(3)=15.0, p<0.01].
A lower proportion of the o12 months subgroup re-
covered than other subgroups in the same period from
onset. Regardless of duration, GAD is a chronic dis-
order, with only half of those affected recovering after
about 18–24 years post-onset in developed countries.
An even more chronic course was found in developing
countries, where the median time to recovery was
24–29 years post-onset. This was most pronounced for
the o12 months subgroup where the median time to
recovery was as much as 50 years after onset. A special
finding in developed countries was that the 1–2 and
3–5 months subgroups had a lower proportion of re-
covery than the 6–11 months subgroup; i.e. the two
subgroups took longer to reach the same proportion of
recovery as the 6–11 months subgroup (details of re-
covery curves not shown, but available on request).
Discussion
Several limitations of the present study are worthy of
note. One is the retrospective assessment of the onset,
duration and number of anxiety episodes. Although
the probing strategy we used has been shown to im-
prove recall of information such as age of onset
(Knauper et al. 1999), it was possible that the quality of
respondents’ recall varied. Recall bias may have been
especially likely for respondents with multiple lifetime
episodes of varying duration that occurred over a long
period of time, or for recollection of more complex
diagnostic criteria, such as the number of months
when symptoms were present more days than not
(Ruscio, 2002). A related limitation is the current lack
of consensus among clinicians and researchers about
when a GAD episode should be considered to have
ended. The operational definition that we used
(1 month of full symptom remission) was somewhat
arbitrary and may have overestimated duration by
requiring a full month without any symptoms rather
than a month when symptoms occurred on fewer than
Table 5. Association between generalized anxiety disorder defined with specific duration and risk of subsequent first onset of other
disorders, in developed and developing countriesa
Duration of generalized anxiety
Wald x2,
df=3 p1–2 months 3–5 months 6–11 months o12 months
Developed countries
Any other anxiety disordersb 2.4 (1.9–3.0) 2.5 (1.9–3.4) 2.8 (2.0–4.0) 3.7 (3.1–3.4) 13.4* <0.01
Any mood disordersc 2.1 (1.7–2.7) 2.8 (2.0–3.8) 2.6 (1.9–3.6) 3.3 (2.8–4.0) 10.3* 0.02
Any substance-use disordersb 2.3 (1.7–3.2) 1.7 (1.0–2.7) 1.5 (0.9–2.6) 2.7 (2.0–3.5) 5.6 0.13
Any impulse-control disordersd 4.8 (2.5–9.1) 3.7 (0.9–15.7) 1.4 (0.3–7.4) 2.1 (0.9–5.3) 3.7 0.29
Any disordersb 2.1 (1.5–2.9) 1.8 (1.0–3.2) 1.6 (0.9–2.8) 3.4 (2.6–4.5) 10.1* 0.02
Developing countries
Any other anxiety disordersb 3.6 (2.0–6.5) 4.5 (2.1–9.8) 2.9 (1.5–5.4) 6.4 (4.5–9.2) 6.6 0.09
Any mood disordersc 3.7 (2.4–5.6) 1.3 (0.6–2.8) 2.5 (1.2–5.3) 4.2 (3.0–6.0) 9.1* 0.02
Any substance-use disordersb 2.0 (1.0–4.0) 2.2 (0.7–6.4) 1.9 (0.8–4.4) 3.4 (1.9–6.0) 2.2 0.54
Any impulse-control disordersd 1.1 (0.2–7.3) 2.0 (0.5–9.0) 0.8 (0.1–6.3) 11.3 (4.0–31.9) 8.6* 0.04
Any disordersb 2.0 (1.0–3.7) 3.9 (1.0–15.5) 4.1 (2.2–7.9) 4.7 (3.0–7.3) 4.9 0.18
df, Degrees of freedom.
Values are given as odds ratio (95% confidence interval).
a Based on bivariate analysis using a discrete-time survival model with person-year as the unit of analysis, controlling for
person-year, person-year squared, age at interview, sex. No distinctions are made between respondents whose target disorder
was active versus remitted at the time that the secondary disorder began. Disorders are diagnosed without diagnostic
hierarchies.
bWeighted on part 2 sample (developed n=27 545, developing n=15 579).
cWeighted on part 1 sample (developed n=50 791, developing n=34 057).
dWeighted on part 2 sample in age 44 years or younger (developed n=14 262, developing n=10 121).
* Significant at p<0.05.
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half of the days. Although our use of a fully structured
diagnostic instrument and rigorously trained lay inter-
viewers enhanced reliability in the cross-national as-
sessment of mental disorders, the CIDI does not allow
symptom clarification and differential diagnosis in
the same manner as clinician-administered semi-
structured interviews. This might have resulted in
inflated associations between GAD and other dis-
orders. While clinical reappraisal studies have sug-
gested reasonably good concordance between CIDI
and SCID diagnoses, these studies were performed in
only a subset of WMH countries, including China,
France, Italy, Spain and the USA (Haro et al. 2006 ; Lee
et al. 2007b).
With these limitations in mind, the present study
showed that the impact of shifting the GAD duration
criterion is quite similar across developing and devel-
oped countries, though a few differences between the
two country groups are worthy of mention. One is the
lower prevalence of both lifetime and 12-month GAD
in developing countries. This may reflect a generally
lower level of psychiatric morbidity (Demyttenaere
et al. 2004), higher diagnostic thresholds related to re-
spondents having a lower level of mental health liter-
acy, or other methodological factors that lead to a
downward bias in the estimation of anxiety disorders
in these countries (Shen et al. 2006 ; Chang et al. 2008).
Levels of GAD-related impairment also differed be-
tween developed and developing countries. Respon-
dents with GAD in developing countries reported less
impairment on the SDS, despite reporting a similar
number of out-of-role days as their counterparts
in developed countries. Unlike out-of-role days,
which are more objectively defined, there may be
cross-cultural differences in appraising and respond-
ing to questions about how symptoms have interfered
with home management, work, social life and per-
sonal relationships. The final difference was the lower
treatment rate of GAD in developing countries. This is
expected, as high levels of unmet needs for mental
health treatment are pervasive in low-income coun-
tries (Wang et al. 2007).
These differences in prevalence, impairment and
treatment notwithstanding, GAD prevalence esti-
mates showed similar increases in both groups of
countries as the duration criterion was broadened.
Moreover, varying the duration of GAD resulted in
very similar changes in onset, course, impairment, co-
morbidity and recovery rate in developing and devel-
oped countries. The findings are consistent with pre-
vious western studies (Bienvenu et al. 1998 ; Maier et al.
2000 ; Carter et al. 2001; Kessler et al. 2005) and extend
these studies by providing findings from developing
countries that conducted surveys using the same
methodology.
Compared with respondents who met the DSM-IV
duration requirement of 6 months, respondents with
GAD duration of 3–5 months had generally similar
age of onset, symptom severity, symptom persistence,
role impairment, co-morbidity with other mental dis-
orders, suicidality, treatment pattern and course of
recovery. In cases where associations were found be-
tween duration and outcomes, differences between the
3–5 and 6–11 months’ duration subgroups were either
non-monotonic or inconsistent. Moreover, respon-
dents with 3–5 months’ GAD recovered more slowly
than those with 6–11 months’ GAD in developed
countries. This is a further indication that GAD of
<6 months’ duration is not necessarily a milder form
of the disorder.
Unlike several western studies that examined
durations of 1–6 months and did not find duration to
relate to the psychopathological profile of GAD
(Bienvenu et al. 1998), we found that the o12 months
subgroup was more impaired and slower to recover
than the other subgroups. In developing countries,
where treatment was greatly limited, the median time
to recovery was particularly prolonged. Our findings
therefore do not completely support the view that
duration is of no utility in defining the severity of
GAD (Rickels & Rynn, 2001). Because this subgroup
represents a chronic form of GAD that is already cap-
tured by the DSM-IV 6-month criterion, it is not the
focus of the controversy surrounding the duration
criterion of GAD. Nevertheless, our findings suggest
that episode durations of o1 year may reflect a more
severe form of GAD. It is possible that this more
chronic form of the disorder may be associated with
higher rates of co-morbid axis II pathology or other
interpersonal difficulties (Yonkers et al. 2000).
Questions related to the duration of GAD are affec-
ted by how persistence and termination of episodes
are defined. The DSM-IV duration criterion for GAD
requires that excessive anxiety and worry occur ‘more
days than not for at least 6 months’ (APA, 2000). If
‘more days than not ’ is interpreted as more than half
of the time, the criterion does not specify how the
more than 50% of days (i.e. 3 of the 6 months) with
anxiety symptoms should be distributed within the
6-month period, nor whether brief periods of complete
symptom remission may occur. This is in contrast to
the more explicit duration criterion of major depress-
ive episode, in which depressed mood or anhedonia
must be present ‘most of the day, nearly every day’
for 2 weeks (APA, 2000). Studies with clinical samples
from specialized treatment centers suggest that most
patients with DSM-III-R GAD experience anxiety
more days than not (Yonkers et al. 1996), but it is un-
clear whether the same level of persistence would be
found in community-based samples. In fact, our data
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suggest considerable variability in the course as well
as duration of GAD symptoms, with the average re-
spondent in the 1–2 months’ duration subgroup re-
porting a pattern of short episodes of anxiety recurring
over many years. However, because subjective per-
ceptions of symptom persistence do not always corre-
spond to the objective number of days with anxiety
(Ruscio, 2002), there is a need for prospective research
that tracks symptoms on a daily basis for 6 months or
more to characterize the course and refine the criteria
for GAD.
Our findings have implications for the duration re-
quirement of GAD in DSM-V. If the 6-month duration
criterion is maintained, we recommend that DSM-V
provide greater description of the longitudinal varia-
bility of the course of anxiety. Instead of ‘more days
than not for at least 6 months’, more emphasis can be
put on the clinical significance, for example, of in-
dividuals who suffer from recurrent short episodes of
impairing anxiety.
Shortening the duration criterion in DSM-V – to
1 month, for example – will increase the proportion of
people who are diagnosed with GAD in both devel-
oped and developing countries and facilitate earlier
clinical diagnosis. This modification is supported by
our findings that individuals whose symptom dur-
ation falls short of the DSM-IV criterion typically suf-
fer moderate to severe symptoms and impairment and
have a risk of future mental disorders that is no dif-
ferent than that of respondents who meet the current
duration criterion. Although an episode duration of
<6 months may be considered subthreshold by DSM-
IV standards, affected individuals are not necessarily
‘ less ill ’. Rather, the DSM-IV definition excludes a
considerable number of people who suffer from GAD
that is <6 months in duration but is nonetheless
impairing and recurrent (Kessler et al. 2005). This
problem is less likely to arise using the Clinical
Descriptions and Diagnostic Guidelines of the ICD-10,
which specify the duration of GAD as ‘variable and
usually a few months’ (WHO, 1993).
There are, however, potential downsides to reduc-
ing the GAD duration requirement. In primary care
settings where general practitioners may not have
sufficient skills to evaluate pathological worry and
quality psychological intervention is barely available,
the adoption of a 1-month duration criterion of GAD
may contribute to the pathologizing of normal stress
responses and indiscriminant pharmacotherapy
(Spitzer & Williams, 1984). The inappropriate treat-
ment of normative anxiety responses to stress is es-
pecially likely to happen in developing countries,
where the quality of mental health services is greatly
limited and the chronic use of benzodiazepine tran-
quillizers is widespread (Lee et al. 2007a).
If the duration criterion of GAD is shortened to
1 month in DSM-V, we would recommend a more
detailed assessment of pathological anxiety that goes
beyond subjective recall of having anxiety ‘more days
than not ’ within the 1-month period, so that clinicians
can target treatment to those who need it most. Such
assessment can be supplemented by the use of di-
mensional anxiety and impairment scales (Rickels &
Rynn, 2001) ; interviews with collateral informants ;
and evaluation of concurrent axis II pathology
(Yonkers et al. 2000), early-onset specific phobias, prior
anxiety episodes (especially those lasting o12
months), and other predictors of onset and persistence
of psychopathology (Kessler et al. 2002). When thus
identified, GAD based on a 1-month duration criterion
should not be equated with a diagnosis of adjustment
disorder, which is often dismissed by clinicians as
having no need for treatment. Instead, it should be
considered a clinically significant condition which
may be especially suitable for early intervention and
prevention of secondary morbidity (Ruscio et al. 2007).
Future trials should examine whether existing ther-
apies would be cost effective in treating 1-month GAD
and preventing its recurrence and progression to
chronicity (Heuzenroeder et al. 2004). Although it is
important to recognize the large inter-individual
variability in stress responses and to assess the treat-
ment needs of individual patients with care, a short-
ened GAD duration criterion may not lead to over-
treatment. In fact, although major depressive episode
has only a 2-week duration criterion, cross-national
community epidemiological surveys have shown a
large treatment gap for depression across the globe.
This gap is especially enormous in developing coun-
tries and argues against the inevitability of medical-
ization in the community (Wang et al. 2007).
Finally, it must be emphasized that the present
study by no means clarifies all pressing issues related
to the diagnostic validity of GAD. Questions about
how pathological anxiety should be defined (e.g. its
excessiveness, diffuseness, controllability and re-
petitiveness) and the number and types of associated
symptoms that should be required for diagnosis (e.g.
somatic symptoms) remain to be examined in future
research.
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